The tumor mutational landscape of BRCA2-deficient primary and metastatic prostate cancer

Carriers of germline BRCA2 pathogenic sequence variants have elevated aggressive prostate cancer risk and are candidates for precision oncology treatments. We examined whether BRCA2-deficient (BRCA2(d)) prostate tumors have distinct genomic alterations compared with BRCA2-intact (BRCA2(i)) tumors. A...

Descripción completa

Detalles Bibliográficos
Autores principales: Kensler, Kevin H., Baichoo, Shakuntala, Pathania, Shailja, Rebbeck, Timothy R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9205939/
https://www.ncbi.nlm.nih.gov/pubmed/35715489
http://dx.doi.org/10.1038/s41698-022-00284-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9205939/
https://www.ncbi.nlm.nih.gov/pubmed/35715489
http://dx.doi.org/10.1038/s41698-022-00284-6

Ejemplares similares